SynthesisMedicine2019
Malignant perivascular epithelioid cell tumor in the female genital tract: Preferred reporting items for systematic reviews and meta-analyses.
Synthesis in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 47 citations in OpenAlex.
- Ultrasound Features of Uterine Perivascular Epithelioid Cell Tumor (PEComa): A Systematic Review.Journal of imaging · 2026Review
- Review
- Postoperative management challenges in concurrent endometrioid carcinoma and PEComa a case report.Discover oncology · 2026Article
- Clinicopathological and molecular features of gynecologic perivascular epithelioid cell tumors: a single-center study.Frontiers in oncology · 2026Article
- Uterine PEComa With Lymphangioleiomyomatosis (LAM)-Like Features: A Case Report.Case reports in pathology · 2026Article
- Article
- Fertility-sparing management of perivascular epithelioid cell tumors: A case report and literature review.Case reports in women's health · 2025Article
- Article
- Characteristics and Treatment of Primary Hepatic Perivascular Epithelioid Cell Tumor (PEComa) in Adults: A Systematic Review.Cancers · 2025Review
- A Case of Ascending Colon Perivascular Epithelioid Cell Tumor Presenting with Intestinal Intussusception: Case Report.Surgical case reports · 2025Article
- Laparoscopic resection of liver PEComa associated with Li‑Fraumeni syndrome: A case report.Biomedical reports · 2024Article
- Conservative treatment in uterine perivascular epithelioid cell tumor of uncertain malignant potential: a case report.Journal of medical case reports · 2024Article
- Malignant Perivascular epithelioid cell tumour of the uterus without TFE3 gene rearrangement: a case report.BMC women's health · 2024Article
- A retrospective clinical analysis of 11 cases of PEComa from different sites.World journal of surgical oncology · 2024Article
- Perivascular Epithelioid Cell Tumor with Uncertain Malignant Potential Arising in the Round Ligament.Diagnostics (Basel, Switzerland) · 2024Article
- Perivascular epithelioid cell tumor of the uterus and pelvic cavity.Frontiers in oncology · 2024Article
- Perivascular epithelioid cell tumor of the uterine cervix identified on the liquid-based cytology: a case report.Diagnostic pathology · 2023Article
- Malignant perivascular epithelioid cell tumor (PEComa) of the uterus.BMC women's health · 2022Article
- Perivascular epithelioid cell tumour and investigation of genetic susceptibility.BMJ case reports · 2022Article
- Perivascular Epithelioid Cell Tumor (PEComa) of Vulva: a Rare Occurrence.Indian journal of surgical oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPerivascular epithelioid cell tumor (PEComa) is a rare mesenchymal tumor, located at various anatomic sites, including the female genital tract. This study aimed to evaluate the clinicopathological characteristics of patients with PEComa arising from the female genital tract.
methodsA retrospective study was conducted in Taipei Veterans General Hospital (Taipei VGH) between 2008 and 2018. All published English cases based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement were also included in the current review.
resultsA total of 114 women from PRISMA and 3 women from Taipei VGH were identified. The uterus was the most commonly involved site (82/114, 71.9%), followed by the cervix (12/114, 10.5%). Immunohistochemical staining showed that nearly all gynecological PEComas were positive for human melanoma black 45 (113/114, 99.1%). More than half of the gynecological PEComas were immunoreactive for desmin (50/85, 58.8%). Multi-modality treatment, including surgery and mammalian target of rapamycin (mTOR) inhibitors as targeted therapy, provided long-term disease-free survival (cure rate ranging from 50% to 100%, based on the different anatomic sites of the female genital tract).
conclusionMulti-modality treatment, including cytoreductive surgery and mTOR inhibitors with/without chemotherapy and/or radiation, should be considered for the management of women with PEComas in the genital tract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.